CTRI/2022/11/047725尚未招募未知
Efficacy and Safety of addition of Dapagliflozin to conventional therapy in patients of Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A placebo controlled double blind study
Sanjay Kumar R0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients willing singned informed consent
- •2.Patients with documented diagnosis of HFpEF and HFmrEF with medical history of symptoms and signs of Heart Failure
- •3.Patients with LVEF 40-60% or evidence of structural Heat disease
排除标准
- •1.Patients who are not willing to sign informed consent.
- •2.Patients with LVEF <40%
- •3.Patients with eGFR <25ml/min/1.73m3
- •4.Patients who are intolerance to Dapagliflozin
研究者
相似试验
尚未招募
不适用
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.CTRI/2022/09/045596Maulana Azad Medical College Delhi
尚未招募
不适用
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.CTRI/2019/05/019286Dr Shashi Panicker
招募中
不适用
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
尚未招募
Unknown
A clinical trial to compare the efficacy of combination therapy of antidiabetic drugs dapagliflozin & metformin versus metformin alone in improving metabolic profile in overweight & obese women with polycystic ovary syndrome.CTRI/2023/06/054098Dr Vishal Agarwal
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500